-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Focus on Chemical Machinery Equipment Network ]
Chemical machinery and equipment network hotspots pay attention to chemical machinery and equipmentPanoramic review of the biopharmaceutical industry chain: the upstream pharmaceutical equipment industry is weak
A panoramic review of the biopharmaceutical industry chain: the upstream pharmaceutical equipment industry is weak in pharmaceutical equipmentThe upstream pharmaceutical foundation of biopharmaceuticals is mainly composed of raw materials, pharmaceutical equipment and biotechnology.
Among them, the raw materials are mainly natural biological materials, including microorganisms, human bodies, animals, plants, marine organisms, etc.
; biopharmaceutical equipment mainly includes biological reactions filter medium, sterilization equipment, freezers and the like, wherein the bioreactor is a biopharmaceutical core and critical equipment.
The midstream of the industry chain is the R&D and production link of biopharmaceuticals.
The products of biopharmaceuticals mainly include monoclonal antibodies, vaccines, recombinant proteins, blood products, and diagnostic reagents.
The downstream consumer tier is mainly the sales and consumption of medicines.
The CRO, CMO and CSO of biomedical outsourcing services involve the middle and lower reaches of the biopharmaceutical industry chain.
reactorAmong them, the raw materials are mainly natural biological materials, including microorganisms, human bodies, animals, plants, marine organisms, etc.
; biopharmaceutical equipment mainly includes biological reactions filter medium, sterilization equipment, freezers and the like, wherein the bioreactor is a biopharmaceutical core and critical equipment.
The midstream of the industry chain is the R&D and production link of biopharmaceuticals.
The products of biopharmaceuticals mainly include monoclonal antibodies, vaccines, recombinant proteins, blood products, and diagnostic reagents.
The downstream consumer tier is mainly the sales and consumption of medicines.
The CRO, CMO and CSO of biomedical outsourcing services involve the middle and lower reaches of the biopharmaceutical industry chain.
With the vigorous development of the biopharmaceutical industry, the market demand for biopharmaceutical equipment in China has also expanded.
However, while full of opportunities, the biopharmaceutical equipment industry is facing greater challenges.
The market lack of equipment is more serious, the overall innovation ability of the industry is relatively weak, and the trust of pharmaceutical companies in domestic biopharmaceutical equipment is low.
Mainly rely on imports.
Most of the market share of biopharmaceutical equipment is occupied by European, American and Japanese companies.
China's biopharmaceutical equipment is controlled by others and urgently needs to get rid of the source of biopharmaceutical dependence.
Biopharmaceutical equipment includes Pall, Sartorius, Tofflon, Chutian Technology, and General Electric.
However, while full of opportunities, the biopharmaceutical equipment industry is facing greater challenges.
The market lack of equipment is more serious, the overall innovation ability of the industry is relatively weak, and the trust of pharmaceutical companies in domestic biopharmaceutical equipment is low.
Mainly rely on imports.
Most of the market share of biopharmaceutical equipment is occupied by European, American and Japanese companies.
China's biopharmaceutical equipment is controlled by others and urgently needs to get rid of the source of biopharmaceutical dependence.
Biopharmaceutical equipment includes Pall, Sartorius, Tofflon, Chutian Technology, and General Electric.
A number of outstanding biopharmaceutical companies have emerged in the midstream R&D and manufacturing layer of the biopharmaceutical industry chain, such as WuXi AppTec, WuXi Biologics, BeiGene, China Biopharmaceuticals, Kangtai Bioproducts, Hualan Biotechnology, Kanglong Chemical, and Wantai Biopharmaceuticals, Ganli Pharmaceuticals, Junshi Biologicals, etc.
Regional heat map of the biopharmaceutical industry chain: low industry concentration
There are many companies in China's biopharmaceutical industry, but the overall concentration is relatively low.
According to publicly available data, the enterprises above the midstream of the biopharmaceutical industry chain have been sorted out to obtain a regional heat map in Figure 3.
From the perspective of regional distribution, there are obviously more outstanding biopharmaceutical companies distributed in Beijing, Shanghai, Guangdong, Jiangsu and other regions.
The biopharmaceutical industry requires a high level of technology, abundant natural resources, and high concentration of talents.
According to publicly available data, the enterprises above the midstream of the biopharmaceutical industry chain have been sorted out to obtain a regional heat map in Figure 3.
From the perspective of regional distribution, there are obviously more outstanding biopharmaceutical companies distributed in Beijing, Shanghai, Guangdong, Jiangsu and other regions.
The biopharmaceutical industry requires a high level of technology, abundant natural resources, and high concentration of talents.
In recent years, some biopharmaceutical R&D and production companies in China have achieved good results.
Among them, the regions are as follows: Baiji Shenzhou, China Biotechnology, Beijing Tiantan, Kanglong Chemical, Shenzhou Cell, etc.
are located in Beijing; Junshi in Shanghai Biology, Shanghai RAAS, Fosun Pharmaceutical, etc.
; Jiangsu Wuxi Biologics, Hengrui Pharmaceuticals, Cinda Biology, Borui Pharmaceuticals, etc.
; Guangdong Taikang Biology, Livzon Pharmaceuticals, Boji Pharmaceuticals, etc.
; Henan Hualan Biology , Qilu Pharmaceutical in Shandong, Watson Biological in Yunnan, Zhifei Biological in Chongqing, Kelun Pharmaceutical and Huashen Technology in Sichuan, etc.
Among them, the regions are as follows: Baiji Shenzhou, China Biotechnology, Beijing Tiantan, Kanglong Chemical, Shenzhou Cell, etc.
are located in Beijing; Junshi in Shanghai Biology, Shanghai RAAS, Fosun Pharmaceutical, etc.
; Jiangsu Wuxi Biologics, Hengrui Pharmaceuticals, Cinda Biology, Borui Pharmaceuticals, etc.
; Guangdong Taikang Biology, Livzon Pharmaceuticals, Boji Pharmaceuticals, etc.
; Henan Hualan Biology , Qilu Pharmaceutical in Shandong, Watson Biological in Yunnan, Zhifei Biological in Chongqing, Kelun Pharmaceutical and Huashen Technology in Sichuan, etc.
For more data, please refer to the "China Biopharmaceutical Industry Market Demand Forecast and Investment Strategic Planning Analysis Report" by the Qianzhan Industry Research Institute.
At the same time, the Qianzhan Industry Research Institute also provides industrial big data, industrial planning, industry declaration, industrial park planning, industrial investment promotion, etc.
solution.
At the same time, the Qianzhan Industry Research Institute also provides industrial big data, industrial planning, industry declaration, industrial park planning, industrial investment promotion, etc.
solution.
Original title: [Dry goods] Biopharmaceutical industry chain panoramic combing and regional heat map
